Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar-arterial oxygen gradient (AaPO(2)) at 3 months in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Transpl
Main Authors: Kawut, Steven M., Ellenberg, Susan S., Krowka, Michael J., Goldberg, David, Vargas, Hugo, Koch, David, Sharkoski, Tiffany, Al-Naamani, Nadine, Fox, Alyson, Brown, Robert, Levitsky, Joshua, Oh, Jae K., Lin, Grace, Song, Nianfu, Mottram, Carl, Doyle, Margaret F., Kaplan, David E., Gupta, Samir, Fallon, Michael B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6910867/
https://ncbi.nlm.nih.gov/pubmed/30816637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/lt.25438
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados